Want to learn how Elsie Biotechnologies is advancing the future of oligonucleotide therapeutics? Join us on March 21st for our webinar with Elsie Biotechnologies, an industry leader in oligonucleotide therapeutics, who recently partnered with GSK to revolutionize the development of safer, more effective therapeutics, while pushing the boundaries of drug discovery. During this webinar, we’ll hear from Dillon Flood, Elsie’s Co-Founder and Scientific Director, to learn more about their platform, their recent partnership with GSK, and the future of oligonucleotide therapies. Register here to save your seat: https://lnkd.in/gUriiEav
LatchBio’s Post
More Relevant Posts
-
Our very own Associate Director of CMC, Ashley Taylor, highlighted this article by LifeTein.com on the benefits of stapled peptides. Stapled peptides are breaking new ground in drug development, offering enhanced stability and efficacy for targeting previously undruggable interactions. What are your thoughts on the future of peptide therapeutics? Check out the article and let us know! https://lnkd.in/embS6_di #BiotechInnovation #PeptideTherapeutics #DrugDevelopment
-
-
Scientist and Engineer | Executive MBA | Pharma and Biotech Market Research | Science Liaison | Technical Writer | Medical Communications
💊 𝐒𝐦𝐚𝐥𝐥 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐞𝐬 𝐝𝐨𝐦𝐢𝐧𝐚𝐭𝐞 𝐚𝐦𝐨𝐧𝐠 𝐅𝐃𝐀 𝐧𝐨𝐯𝐞𝐥 𝐝𝐫𝐮𝐠 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 𝐢𝐧 2023 Among the FDA & CDER 2023 novel drug approvals, oncology and haematology are the dominant therapeutic areas. 2023 brought more diversity in terms of modalities, especially bringing an increase in nucleotide-based therapeutics. According to 𝘕𝘢𝘵𝘶𝘳𝘦 𝘙𝘦𝘷𝘪𝘦𝘸𝘴 𝘋𝘳𝘶𝘨 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺, the FDA approved in 2023: ⚆ 34 small molecule products ⚆ 17 protein-based products ⚆ 4 oligonucleotides 𝘞𝘩𝘢𝘵 𝘵𝘳𝘦𝘯𝘥𝘴 𝘪𝘯 𝘵𝘦𝘳𝘮𝘴 𝘰𝘧 𝘮𝘰𝘥𝘢𝘭𝘪𝘵𝘪𝘦𝘴 𝘤𝘢𝘯 𝘸𝘦 𝘦𝘹𝘱𝘦𝘤𝘵 𝘪𝘯 2024? Source: https://lnkd.in/eT_j65eT #pharma #drugdevelopment #biotech #innovation #business #clinicaltrials #womeninbusiness #drjojo
-
-
Gastroenteropancreatic Neuroendocrine Tumors Market to Showcase a Significant Growth by 2032, Evaluates DelveInsight | Key Players - Eli Lilly and Company, Phanes Therapeutics, Camurus AB, Advanced Accelerator Applications, PharmaMar: The global GEP-NET therapeutics market is further expected to increase by the major drivers such as rising incident population, technological advancements, increased funding for new drug development and clinical trials, increasing awareness among common people, increasing research...
-
IRLAB Therapeutics AB In our recent analysis conducted with EQL desktop, we have reviewed IRLAB Therapeutics AB, a biopharmaceutical company based in Gothenburg, Sweden. Current Developments: IRLAB's development pipeline includes Mesdopetam in phase IIb/III trials for dyskinesia in Parkinson’s disease and several preclinical initiatives aimed at neurodegenerative disorders. Strategic Approach: Our research provides an objective look into IRLAB’s strategic methods and the progress of their clinical trials, presenting a clear picture of their operations and potential implications for patient care. Sign up today: https://lnkd.in/dJ8zhDrP #ResearchwithAI #EQL #Irlab #marketintelligence
-
-
Business Development Manager @ Alcami | Biotech Sales Professional | MS in Applied Life Sciences
In recent years, the biopharmaceutical sector has seen an expansive development of oligonucleotides as human medications, serving both therapeutic and vaccine purposes. This category includes a diverse array of products such as small interfering RNAs (siRNA) and microRNA (miRNA), plasmid DNA (pDNA), and messenger RNA (mRNA) vaccines. Discover the intricacies involved in the analytical testing of oligonucleotide products and the varying degrees of support provided by William Boomershine, Ph.D., in his latest whitepaper titled Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO
-
-
Keeping ahead of the rapidly-evolving field of drug discovery is no easy feat. But with 90% of potential drug targets still inaccessible, now is the perfect time to explore innovative solutions. Download our whitepaper to unveil strategies for targeting these “undruggables”—from multi-specific drugs, PROTACs, oligonucleotide therapeutics, and PPI modulators. Learn more: https://cytiva.link/1b163
-
-
Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma: Pfizer acquired Seagen for $43 billion AbbVie invested over $10 billion in ImmunoGen Merck committed $4 billion upfront, with a potential total of $22 billion, for a stake in three of Daiichi Sankyo’s ADCs Wondering what all the fuss is about and why would-be investors are priced out of the market? Read our report now for insights on the market landscape, including complexities in the field and key deal drivers. Find out who’s top of the pile and who’s poised to make the next move.
-
When considering new clinical targets, #formulations, and delivery methods for #RNA-based therapeutics, you need a comprehensive view of the IP landscape to protect your investments. Read our new executive summary to explore #IP trends and opportunities in this space. https://ow.ly/JXk550QLFnn
IP trends and opportunities: RNA therapeutics
cas.org
-
Keeping ahead of the rapidly-evolving field of drug discovery is no easy feat. But with 90% of potential drug targets still inaccessible, now is the perfect time to explore innovative solutions. Download our whitepaper to unveil strategies for targeting these “undruggables”—from multi-specific drugs, PROTACs, oligonucleotide therapeutics, and PPI modulators. Learn more: https://cytiva.link/1b163
-
-
Discovery Medical Sales Account Manager at Cytiva | Boston West & South | Platinum Sales Club-Rookie of the Year Award 2020
Keeping ahead of the rapidly-evolving field of drug discovery is no easy feat. But with 90% of potential drug targets still inaccessible, now is the perfect time to explore innovative solutions. Download our whitepaper to unveil strategies for targeting these “undruggables”—from multi-specific drugs, PROTACs, oligonucleotide therapeutics, and PPI modulators. Learn more: https://cytiva.link/1b163
-
NS MEDICO INDIA FOUNDATION,Registered,CSR,NITI AAYOG,80G, 12A, GST,EANUDAN
5mo💐💐💐